Ambrx Biopharma Inc ADR (AMAM)

NYSE
2.56
+0.11(+4.49%)
After Hours
2.60
+0.08(+3.17%)
- Real-time Data
  • Volume:
    9,783
  • Day's Range:
    2.44 - 2.62
  • 52 wk Range:
    2.25 - 18.86

AMAM Overview

Prev. Close
2.45
Day's Range
2.44-2.62
Revenue
7.45M
Open
2.44
52 wk Range
2.25-18.86
EPS
-1.76
Volume
9,783
Market Cap
94.54M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
10,939
P/E Ratio
-
Beta
-
1-Year Change
-85.42%
Shares Outstanding
38,588,649
Next Earnings Date
Aug 31, 2022
What is your sentiment on Ambrx Biopharma?
or
Market is currently closed. Voting is open during market hours.

Ambrx Biopharma Inc ADR Company Profile

Ambrx Biopharma Inc ADR Company Profile

Employees
70

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient’s own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuySellSell
SummaryStrong BuyStrong BuyStrong BuySellStrong Sell